Semaglutide also benefits from a longer real-world safety track record (approved for weight loss since 2021)
News provided by Novo Nordisk Oct 17, 2025, 17:15 ET Rybelsus (semaglutide) tablets 7 mg or 14 mg, the only FDA-approved oral GLP-1 medicine available, now indicated to reduce the risk of major adverse cardiovascular events (MACE) such as CV death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events 1 In the SOUL trial, oral semaglutide 14 mg reduced the risk of MACE by 14% compared to placebo, in addition to standard therapies Milestone underscores the robust data supporting oral semaglutide and demonstrates Novo Nordisk's cardiometabolic leadership and commitment to people living with chronic disease PLAINSBORO, N.J
How many have you completed? The assumption, if you saw this person come in and you didnt know anything, you would presume, Oh, theyre not active
Save the heartier recipes for mid-week when your body has adjusted
Injection Administration The compound is delivered into the subcutaneous tissue in a controlled and steady manner
CLICK HERE TO DOWNLOAD THE FOX NEWS APP "And then I realized the very first time I took the GLP-1 that oh, theyre not even thinking about it